ConductScience.org, home

Paper39199656

Perioperative Predictive Factors for Tumor Regression and Survival in Non-Small Cell Lung Cancer Patients Undergoing Neoadjuvant Treatment and Lung Resection.

Damirov F and 10 others. Cancers (Basel), 2024. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Perioperative Predictive Factors for Tumor Regression and Survival in Non-Small Cell Lung Cancer Patients Undergoing Neoadjuvant Treatment and Lung Resection. Papers, record 39199656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39199656

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Perioperative Predictive Factors for Tumor Regression and Survival in Non-Small Cell Lung Cancer Patients Undergoing Neoadjuvant Treatment and Lung Resection.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Relative citation ratio, by iCite
0.0, provisional
iCite
Revised in PubMed
2024-09-03
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Damirov FFuadhttps://orcid.org/0000-0001-6982-2369
2Stoleriu MGMircea Gabriel
3Manapov FFarkhad
4Boedeker EEnole
5Dreher SSascha
6Gerz SSibylle
7Hehr TThomas
8Sandner EEvelin
9Ott GGerman
10Hatz RARudolf Alexander
11Preissler GGerhard

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References42

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134811893Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.Asia Pac J Clin Oncol2022https://conductscience.org/library/papers/34811893PubMed
237903504Association between pathologic response and survival after neoadjuvant therapy in lung cancer.Nat Med2024https://conductscience.org/library/papers/37903504PubMed
324384493Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.Lancet Oncol2014https://conductscience.org/library/papers/24384493PubMed
435543472Role of fluorodeoxyglucose-positron emission tomography in predicting the pathological response and prognosis after neoadjuvant chemoradiotherapy for locally advanced non-small-cell lung cancer.Interact Cardiovasc Thorac Surg2022https://conductscience.org/library/papers/35543472PubMed
521676484Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer.Lung Cancer2011https://conductscience.org/library/papers/21676484PubMed
622997251Surgery on unfavourable persistent N2/N3 non-small-cell lung cancer after trimodal therapy: do the results justify the risk?Interact Cardiovasc Thorac Surg2012https://conductscience.org/library/papers/22997251PubMed
735403841Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.N Engl J Med2022https://conductscience.org/library/papers/35403841PubMed
825110337Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer.Ann Thorac Surg2014https://conductscience.org/library/papers/25110337PubMed
928123901Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients.Oncoimmunology2016https://conductscience.org/library/papers/28123901PubMed
1027448762
The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer.
J Thorac Oncol2016https://conductscience.org/library/papers/27448762PubMed
1126527789
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
J Clin Oncol2015https://conductscience.org/library/papers/26527789PubMed
1211713138Grading of tumor regression in non-small cell lung cancer : morphology and prognosis.Chest2001https://conductscience.org/library/papers/11713138PubMed
1318721582The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives.Ann Thorac Surg2008https://conductscience.org/library/papers/18721582PubMed
1438090369Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives.Cancer Innov2023https://conductscience.org/library/papers/38090369PubMed
1519632716Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.Lancet2009https://conductscience.org/library/papers/19632716PubMed
169341895Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment.J Cancer Res Clin Oncol1997https://conductscience.org/library/papers/9341895PubMed
1726200453Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors.J Thorac Oncol2015https://conductscience.org/library/papers/26200453PubMed
1826543609Clinical outcomes of surgery after induction treatment in patients with pathologically proven N2-positive stage III non-small cell lung cancer.J Thorac Dis2015https://conductscience.org/library/papers/26543609PubMed
1927987576Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC.Lung Cancer2016https://conductscience.org/library/papers/27987576PubMed
2020100967
Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
J Clin Oncol2010https://conductscience.org/library/papers/20100967PubMed

See all 42 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39199656

GET https://conductscience.org/api/papers/v1/39199656/references?page=2